Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects With Palmoplantar Pustulosis
Conditions
Interventions
RIST4721
Placebo
Locations
51
United States
Total Skin & Beauty Dermatology Center, PC
Birmingham, Alabama, United States
Dermatology Trial Associates
Bryant, Arkansas, United States
Cosmetic Laser Dermatology
San Diego, California, United States
Clinical Science Institute
Santa Monica, California, United States
Driven Research LLC
Coral Gables, Florida, United States
Encore Medical Research, LLC
Hollywood, Florida, United States
Start Date
January 5, 2022
Primary Completion Date
February 13, 2023
Completion Date
March 6, 2023
Last Updated
June 29, 2023
NCT05710185
NCT04459507
NCT03972280
NCT03988335
Lead Sponsor
Aristea Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions